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In a multicentre study of 143 asthmatic children treated with 
inhaled corticosteroids (ICS) with or without nasal steroids (NS), 
two-thirds were found to have biochemical hypothalamic-pituitary-
adrenal axis suppression (HPAS). With the exception of eight who 
were frankly hypocortisolaemic (as defined by an early-morning 
serum cortisol level <83 nmol/L), all were assessed by the overnight 
metyrapone test (ONMTPT).[1] Predictors of HPAS were NS use 
(odds ratio 3.7 (logistic regression)), body mass index (BMI), 
and adherence to ICS and NS (p=0.48, p<0.001 and p=0.002, 
respectively (linear regression)). At physiological doses (equating 
a cortisol production rate of 3.0 - 10.6 mg/m2/d (mean (2 standard 
deviations)[2]) or a budesonide equivalent of 296 - 848 µg/m2/d), the 
post-metyrapone adrenocorticotropic hormone (ACTH) level was 
inversely correlated to the daily ICS + NS dose, adjusted for body 
surface area (r=–0.29, p<0.002). At supraphysiological doses this 
correlation was lost.
All hypocortisolaemic patients were to be started on 
hydrocortisone (HC) replacement of 8 mg/m2/d, increasing doses 
during stress. Subsequently steroid-sparing medications, i.e. long-
acting beta-agonists, leukotriene receptor antagonists or long-
acting theophyllines, were to be introduced, followed by a reduction 
of ICS doses (omalizumab was not available to the South African 
public sector). To prevent suppression of the early-morning ACTH 
surge through nocturnal dosing, single morning doses of ICS 
were recommended. Nasal beclomethasone dipropionate was to 
be replaced by a single morning dose of a newer-generation NS, 
e.g. fluticasone propionate. After about a year, asthma control and 
adherence permitting, HC doses were to be discontinued and early-
morning serum cortisol repeated. If normal, the patients were to 
undergo a repeat ONMTPT.
Objectives
To establish whether hypocortisolaemia and HPAS in asthmatic 
children on steroids could be completely reversed by therapy 
modification without sacrificing asthma control.
Methods
After ~1 year of HC replacement and treatment modification, HC 
administration to the eight hypocortisolaemic patients seen at the 
asthma clinics of Red Cross War Memorial Children’s Hospital or 
Tygerberg Hospital was discontinued and their early-morning serum 
cortisol repeated, provided their asthma was well controlled and the 
ICS and NS dose stable for 3 - 6 months. If not, doses were increased 
and testing deferred. After serum cortisol normalised, modification 
of asthma therapy continued and, asthma control permitting, the 
ONMTPT was repeated. An adequate response was defined by a 
rise of ACTH from baseline to >106 pg/mL (23.3 pmol/L)[3] and an 
11-deoxycortisol (11DOC) rise to >208 nmol/L.[4] If the response was 
inadequate, ONMTPTs were repeated at ~6-monthly intervals until 
adequate. A retrospective folder review was then performed. The 
following data were extracted: BMI standard deviation score (SDS), 
asthma score, FEV1 (forced expiratory volume in 1 second), adherence 
to therapy, daily steroid type and dose, treatment modification, serum 
cortisol, final ONMTPT result and time taken until normalisation. 
The asthma score was determined using the Asthma Control 
Questionnaire, which defines optimal control as a score <0.75. [5] 
During the previous study, adherence was formally assessed by 
enquiring how many doses had been omitted in the preceding week.[1] 
In the clinical setting, poor adherence was defined as an admission by 
a child of having omitted any number of doses during the preceding 
week. The patients’ inhalation technique was evaluated and, if 
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necessary, corrected during every clinic 
visit. The total daily steroid load was 
expressed as HC equivalent.[1]
Ethical approval
This case series is part of a larger study 
approved by the Health Research Ethics 
Committee of Stellenbosch University 
(ref. no. N06/09/184) and the Research 
Ethics Committee of the University of 
Cape Town (ref. no. 276/2003). The 
original consent included possible treat-
ment modification. Consent for repeat 
metyrapone testing was reobtained in 
each case. The Health Research Ethics 
Committee required no additional 
consent (all retested patients were from 
Tygerberg Hospital).
Results
Eight patients with hypocortisolaemia 
were identified during the previous 
study. Of these, one was lost to follow-up 
and one was excluded because a repeat 
ONMTPT was not done. The remaining 
three boys and three girls (all of mixed 
ancestry) were followed up by the author 
at the same centre (Tygerberg Children’s 
Hospital). The ages ranged from 5.2 to 
12.9 years (mean 8.8, median 8.3). Before 
hypocortisolaemia was diagnosed, the 
children had been on ICS for 0.3 - 9.1 years 
(mean 3.3, median 2.1) and the number of 
prednisone courses received ranged from 
0 to 7 (mean 4, median 5). BMI, asthma 
control, therapy and modification over 
time are listed in Table 1. Height and 
height velocity SDS on follow-up are not 
reported, because these were previously 
shown not to correlate with the post-
metyrapone ACTH.[1,6] Daily steroid load 
and HPA function over time are shown 
in Table 2. HC treatment duration was 
3 - 30 months.
By the last follow-up visit, the median 
daily steroid load had decreased by 
~40% but increased in one child who 
was not adhering to therapy (Table 2). 
At the same visit, the asthma score of 
the group had improved by about the 
same percentage, but the FEV1 remained 
similar (Table  1). ICS doses were dec-
reased in all the children except one 
with poor adherence. NS doses increased 
overall, partly because good alternatives 
were not available and partly because of 
poor compliance (Table  1). In patient 
3, treated with montelukast, NS could 
be discontinued, while in patient 4 the 
dose could be reduced on changing to 
mometasone furoate. Ta
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Patient 4’s asthma control deteriorated on stopping HC, probably 
owing to poor adherence to ICS + NS therapy, necessitating a 3-day 
course of prednisone and an increase in the ICS dose. Patient 3 
required a 5-day course of prednisone during an exacerbation, 
because the mother had discontinued the prescribed HC. Adherence 
to ICS + NS in this case was also poor, necessitating a second (3-day) 
course of prednisone, prolonged HC cover and increased ICS doses. 
Consequently, recovery of the axis took the longest in patients 3 and 
4 (Table 2).
Patients 1, 3 and 4 were treated with topical betamethasone with or 
without HC for atopic dermatitis. Treatment modification in patients 
1 and 3 consisted of methylprednisolone aceponate initially, followed 
by 10% diluted betamethasone ointment alternating with liquor picis 
carbonis. After modification, patient 4 only required emollients.
Serum cortisol normalised in all patients (Table 2). There was an 
adequate ACTH rise on the ONMTPT in all except patient 4, where 
serum was insufficient. Normalisation of ACTH response can be 
inferred here, since the hypothalamus and pituitary are known to 
recover before the adrenal glands.[7] Judging by the adequate 11DOC 
rise, these had recovered. The post-metyrapone 11DOC normalised 
in all except patient 3. A repeat test confirming total recovery was 
not considered necessary, because the supranormal ACTH response 
implied imminent recovery and the 11DOC result was approaching 
normality.
Discussion
Only one of the children presenting with hypocortisolaemia was 
subjected to a supraphysiological daily steroid load. All others were 
treated with a total steroid dose equal to the daily physiological 
production rate, albeit in the upper range. When disregarding the 
NS contribution, the low ICS dose would generally be deemed safe. [8] 
Hypocortisolaemia has, however, been described in children being 
treated with doses as low as 200 µg beclomethasone dipropionate/
day (2.5 mg HC equivalent) or 400 µg budesonide/day (5 mg HC 
equivalent).[9,10] The suppressed cortisol production is balanced 
by the supply of exogenous steroids. Hypocortisolaemia is one 
step away from adrenal crisis. When cortisol demand outstrips 
exogenous supply, as during an asthma exacerbation, an infection, 
surgery, injury or a burn, a crisis can be precipitated. As these 
stressors are usually unpredictable, HC replacement was prescribed 
as a precaution against a possible crisis. It also allowed for safe 
modification of asthma therapy. Furthermore, HC replacement was a 
protocol requirement, being essential therapy for hypocortisolaemia.
After modification, the median steroid load of the group decreased 
by ~40%, leading to HPAS reversal in all cases. Instead of deteriorating, 
asthma control actually improved. In addition, the number of rescue 
prednisone courses required decreased considerably. The steroid/
non-steroid combination therefore appears to be superior in both 
safety and efficacy compared with the steroid-only therapy given 
before the intervention. Polypharmacy did not seem to have affected 
outcomes adversely. This case series formally documents the reversal 
of HPAS caused by low steroid doses, and the time taken for 
reversal associated with improved asthma control. To the author’s 
knowledge this has not been described previously. The limitations 
of a retrospective report are counterbalanced by a single clinician 
managing all aspects of all cases. Ideally the findings of this case 
series need to be confirmed in a well-designed prospective study, but 
this may be difficult to obtain ethical approval for or to implement.
Could factors other than treatment modification have contributed 
to the recovery of HPAS in these cases? NS use, BMI and adherence to 
ICS and NS have been identified previously.[1] Firstly, NS could only be Ta
bl
e 2
. D
ai
ly
 st
er
oi
d 
lo
ad
 an
d 
hy
po
th
al
am
ic
-p
itu
ita
ry
-a
dr
en
al
 ax
is 
fu
nc
tio
n 
ov
er
 ti
m
e
At
 d
ia
gn
os
is 
of
 h
yp
oc
or
tis
ol
ae
m
ia
At
 fi
rs
t f
ol
lo
w-
up
At
 la
st
 fo
llo
w-
up
Pa
tie
nt
D
ai
ly
 st
er
oi
d 
lo
ad
 in
 
H
C 
eq
u 
(m
g/
m
2 /d
)
C
or
tis
ol
 (n
m
ol
/L
)
D
ai
ly
 st
er
oi
d 
lo
ad
 in
 
H
C 
eq
u 
(m
g/
m
2 /d
)
C
or
tis
ol
 
(n
m
ol
/L
)
Ti
m
e s
in
ce
 
di
ag
no
sis
 (y
r)
D
ai
ly
 st
er
oi
d 
lo
ad
 in
 
H
C 
eq
u 
(m
g/
m
2 /d
)
Po
st
-M
TP
 A
CT
H
 
(p
m
ol
/L
)*
 1
1D
O
C 
(n
m
ol
/L
)†
Ti
m
e s
in
ce
 
di
ag
no
sis
 (y
r)
1
5.
1
27
4.
0
95
1.
1
8.
0
41
23
4
3.
0
2
9.
2
67
4.
0
31
8
0.
7
6.
0
12
2
31
1
1.
7
3
11
.2
63
16
.0
30
3
2.
6
6.
0
11
5
18
8
7.
1
4
9.
1
40
4.
0
36
8
0.
8
4.
0
In
su
ffi
ci
en
t
24
8
6.
5
5
7.
9
42
4.
0
35
9
0.
4
2.
0
17
0
27
6
3.
5
6
9.
9
58
8.
0
22
4
2.
2
4.
0
27
7
33
0
3.
1
M
ea
n
8.
7
50
6.
9
27
8
1.
3
5.
0
14
5‡
26
5
4.
2
M
ed
ia
n
9.
2
50
4.
0
31
1
0.
9
5.
0
12
2‡
26
2
3.
3
H
C 
eq
u 
= 
hy
dr
oc
or
tis
on
e e
qu
iv
al
en
t; 
Po
st-
M
TP
 A
CT
H
 =
 p
os
t-m
et
yr
ap
on
e a
dr
en
oc
or
tic
ot
ro
pi
c h
or
m
on
e l
ev
el;
 1
1D
O
C 
= 
11
-d
eo
xy
co
rt
iso
l.
*N
or
m
al
 A
CT
H
 re
sp
on
se
 >
23
.3
 p
m
ol
/L
 (1
06
 p
g/
m
L)
.
† N
or
m
al
 1
1D
O
C 
>2
08
 n
m
ol
/L
.
‡ B
as
ed
 o
n 
5 
re
su
lts
.
505       June 2018, Vol. 108, No. 6
RESEARCH
discontinued or reduced in two cases. A change in NS use is 
unlikely to have affected outcome, however, because median NS 
dosage actually increased. Secondly, the group’s BMI did not 
increase over time, implying that a BMI change is not likely to 
have contributed to recovery. Thirdly, although the assessment of 
adherence was limited by the different methods used before and 
after intervention, poor adherence could have contributed to the 
reversal in the two additional children known to have been poorly 
compliant after treatment modification. The reason for the poor 
adherence is not known, but is likely to be related to inadequate 
supervision due to the children’s advancing age. On the other hand, 
it also retarded recovery, as exacerbations necessitated prednisone 
courses and higher ICS doses, albeit intermittently. Furthermore, 
as airway diameter increases with age, airway narrowing is less 
severe, resulting in improved asthma control with subsequent lower 
ICS dose and recovery of the axis. However, while asthma was well 
controlled, dosages were reduced to lower steroid exposure and not 
because of improved symptoms.
Conclusions
In this case series, hypocortisolaemia developed in asthmatic 
children while all but one were being treated with steroid doses in 
the physiological range. On reducing the daily steroid load by ~40%, 
hypocortisolaemia and HPAS were effectively reversed in all. Poor 
adherence may have either contributed to or retarded HPA recovery. 
Simultaneously, asthma control improved. A prospective study would 
be ideal to confirm these findings, but may not be feasible.
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